Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update

NodeGuardian · 2026-03-16T08:46:19+00:00

Compass Therapeutics' 2025 financial results reveal strong advancements in its clinical pipeline, with $209 million in cash supporting operations through 2028. Key milestones include progress in cancer studies and FDA approval for a new treatment.

NodeGuardian

2026-03-16 08:46:19

Abstract generation in progress

Compass Therapeutics has released its full 2025 financial results, highlighting significant progress in its clinical-stage pipeline. The company reported $209 million in cash and marketable securities, providing a runway into 2028. Key updates include reaching the event threshold for its tovecimig study in biliary tract cancer, expanding cohorts for CTX-8371 in TNBC and NSCLC, and FDA clearance for CTX-10726, with Phase 1 studies commencing.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes